Hero Fact: Dimdazenil’s primary and only official indication is insomnia. Trazodone’s primary indication is depressive disorders (its sedative effect is secondary), meaning Trazodone cannot be directly recommended or promoted solely as an insomnia treatment.
Dimdazenil effectively reduces time to fall asleep and preserves normal sleep structure. Trazodone focuses on reducing nighttime awakenings and extending deep sleep, particularly for psychiatric patients.
| Criterion | Dimdazenil | Trazodone (Trittico) |
|---|---|---|
| Approved Indication | Insomnia | Depressive Disorders (± Anxiety) |
| Resolving Insomnia | Primary mechanism | Concomitant / side effect |
| Promotional Limits | Direct promotion as sleep aid | Off-label for pure insomnia |
Segment the therapeutic approach based on both clinical efficacy and regulatory guidelines: Position Dimdazenil as the universal, primary treatment for all insomnia patients (especially those struggling to fall asleep). Position Trazodone strictly for patients suffering from depression and anxiety who happen to have comorbid sleep maintenance insomnia, avoiding off-label promotion.